|
SERBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63149999954371E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.96896999999918E-05 |
| Normal-vs-Stage2 |
1.016840E-04 |
| Normal-vs-Stage3 |
9.79369999543067E-08 |
| Normal-vs-Stage4 |
1.60359999723525E-08 |
| Stage1-vs-Stage2 |
4.981800E-01 |
| Stage1-vs-Stage3 |
6.712500E-02 |
| Stage1-vs-Stage4 |
1.300320E-02 |
| Stage2-vs-Stage3 |
5.391600E-01 |
| Stage2-vs-Stage4 |
2.448200E-01 |
| Stage3-vs-Stage4 |
4.992400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.83489999971975E-07 |
| Normal-vs-AfricanAmerican |
3.441600E-02 |
| Normal-vs-Asian |
5.73779999999413E-05 |
| Caucasian-vs-AfricanAmerican |
1.615170E-01 |
| Caucasian-vs-Asian |
7.609600E-01 |
| AfricanAmerican-vs-Asian |
2.452800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.83379999962874E-07 |
| Normal-vs-Female |
8.2866999995268E-07 |
| Male-vs-Female |
2.606800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.587700E-04 |
| Normal-vs-Age(41-60Yrs) |
9.03860000178724E-08 |
| Normal-vs-Age(61-80Yrs) |
2.75729999943408E-08 |
| Normal-vs-Age(81-100Yrs) |
4.763600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.009600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.398500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.726000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.699000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.939400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.949400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.552770E-01 |
| Classical-VS-Follicular |
4.855800E-03 |
| Classical-VS-Other |
2.654400E-01 |
| Classical-VS-Normal |
2.30029999999104E-05 |
| Tall-VS-Follicular |
6.976800E-01 |
| Tall-VS-Other |
7.098400E-01 |
| Tall-VS-Normal |
4.29339999999945E-05 |
| Follicular-VS-Other |
8.976600E-01 |
| Follicular-VS-Normal |
2.27160000032534E-07 |
| Other-VS-Normal |
7.720100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.53550000053993E-07 |
| Normal-vs-N1 |
2.10239999853812E-08 |
| N0-vs-N1 |
9.314100E-02 |
|
|
